Recursion Pharmaceuticals (NASDAQ: RXRX) is doing so specifically within the biotech niche, but the company's efforts haven't ...

Clinical-stage biotechnology firm Recursion announced the release of an open-source biological dataset, RxRx1, which the company has been building for more than five years. The dataset is composed of ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Recursion Pharmaceuticals uses AI to develop drugs. The company's goal is to improve and speed up a process that is slow, expensive, and risky. Most medicines that enter the clinic never make it to ...

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors Salt Lake ...